CTI BioPharma (CTIC) Stock: Falling Hard On Failed Trial

CTI BioPharma Corp (NASDAQ: CTIC) is having an incredibly rough start to the trading session this morning, and for good reason. The company announced that a clinical trial failed to meet its primary endpoint, upsetting investors who are sending the stock spiraling down. Today, we’ll talk about: The clinical results; what we’re seeing from CTIC … Read more

Biotech Stocks Today: MannKind (MNKD), AEterna Zentaris (AEZS), Gilead Sciences (GILD), CTI BioPharma (CTIC)

MannKind Corporation Starts To See Gains MannKind Corporation (NASDAQ: MNKD) MannKind has had tough luck in the market for the past several months. While they have created Afrezza, a key player in medical innovation, the company they contracted for commercialization hasn’t been able to get the sales up. However, I wrote a post in detail … Read more

CTI Biopharma (CTIC) Stock | Is Another Breakout On The Way?

CTI Biopharma (NASDAQ: CTIC) CTIC has had a very interesting time in the market this week. After presenting data from its study known as PERSIST-1 at the ASCO 2015 presentation, the company’s stock climbed Monday. However, we saw a bit of a correction yesterday, followed by relatively flat movement today. So, the big question now … Read more

CTI BioPharma (CTIC) Stock Climbs After ASCO Presentation

CTI Biopharma (NASDAQ: CTIC) This article was originally featured on Warrior Trading News. CTI Biopharma stock is trending up in a big way today after presenting poster presentations at the ASCO 2015 meeting. The presentations announced data from a recent randomized Phase 3 trial looking into pacritinib for the treatment of myelofibrosis. Today, we’ll take … Read more

CTI BioPharma (CTIC) Stock Climbs On Positive Data

CTI Biopharma (NASDAQ: CTIC) | Baxter International’s Bioscience Business (NYSE: BAX) The ASCO 2015 meeting is proving to be a big hit in the world of biotech; and CTIC is making waves. CTI Biopharma and Baxter International’s Bioscience announced data from a Phase 3 registration-directed trial that examined pacritinib for the treatment of myleofibrosis. Today, … Read more